None
Quote | Navidea Biopharmaceuticals Inc. (NYSE:NAVB)
Last: | $0.0779 |
---|---|
Change Percent: | 0.37% |
Open: | $0.08 |
Close: | $0.0779 |
High: | $0.08 |
Low: | $0.0764 |
Volume: | 1,030,238 |
Last Trade Date Time: | 10/05/2023 03:00:00 am |
News | Navidea Biopharmaceuticals Inc. (NYSE:NAVB)
Navidea Biopharmaceuticals , Inc. has completed an exploratory analysis of its Rheumatoid Arthritis Program Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic a...
Navidea Biopharmaceucitals, Inc. will present two proposals for vote in a virtual special meeting of shareholders to be held on July 8, 2024 Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of pre...
Message Board Posts | Navidea Biopharmaceuticals Inc. (NYSE:NAVB)
Subject | By | Source | When |
---|---|---|---|
NEWS -- Navidea Biopharmaceuticals, Inc. Announces Intent to | Paulness | investorshub | 04/28/2023 12:18:35 AM |
NEWS -- Navidea Biopharmaceuticals, Inc. Enters Asset Purchase | Paulness | investorshub | 04/14/2023 11:13:45 AM |
NEWS -- Navidea Biopharmaceuticals, Inc. Hires G2G Ventures | Paulness | investorshub | 03/31/2023 2:49:33 AM |
NEWS -- Q4 2022 Navidea Biopharmaceuticals Inc Earnings Call | Paulness | investorshub | 03/22/2023 1:20:21 PM |
NEWS -- Navidea Biopharmaceuticals to Host Fourth Quarter | Paulness | investorshub | 03/15/2023 12:29:10 PM |
News, Short Squeeze, Breakout and More Instantly...
Navidea Biopharmaceuticals Inc. Company Name:
NAVB Stock Symbol:
NYSE Market:
Navidea Biopharmaceuticals Inc. Website:
Navidea Biopharmaceuticals , Inc. has completed an exploratory analysis of its Rheumatoid Arthritis Program Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic a...
Navidea Biopharmaceucitals, Inc. will present two proposals for vote in a virtual special meeting of shareholders to be held on July 8, 2024 Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of pre...
Navidea Biopharmaceuticals, Inc. announced today the filing of Form 15 to voluntarily deregister and suspend SEC reporting obligations. The company maintains strategic focus on its Fix, Fund, Propel approach. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the &...